Dr. Abigail McElhinny joined Personal Genome Diagnostics as Senior Vice President, Research & Development and Operations in May 2016 from Ventana Medical Systems (Roche Tissue Diagnostics), where she held a number of different roles of increasing responsibilities. At Ventana, Abigail held the position as Vice President of Assay and Reagent Development where she built and led Research & Development teams with the goal of developing new assays for the BenchMark and next generation platforms. Dr. McElhinny represented Ventana on the pivotal PD-L1 Blueprint initiative, and successfully oversaw key scientific projects critical to the business, while her organization doubled in size. Abigail previously served as Senior Project Leader for CDx lifecycle projects, working with regulatory, clinical affairs, quality, and biostatistics teams to build the necessary processes and requirements to support pharma clinical trials and obtain FDA approval for CDx assays, including Ventana’s ALK (D5F3) CDx IHC assay and HER2 Dual ISH assays. Abigail received her Ph.D. from Northeastern University in Immunology and Biochemistry, and completed a post-doctoral fellowship at University of Arizona in Cell Biology, focused on molecular mechanisms of cardiac muscle development, cardiomyopathies and muscle remodeling.
Sessions I’m Presenting
|Affiliation||Personal Genome Diagnostics|